B-Myb is a widely expressed member of the myb oncogene family that has been shown to act as either an activator or repressor of gene transcription in a cell-type-specific fashion. For example, in aortic smooth muscle cells B-Myb represses transcription of the a2(V) collagen gene. Recently, phosphorylation of B-Myb by cyclin A was shown to enhance greatly its ability to transactivate. Here, we have tested the effects of cyclin A on the ability of B-Myb to repress. We report that coexpression of cyclin A abolished repression of the a2(V) collagen promoter, whereas a dominant-negative cyclin-dependent kinase 2 (cdk2) enhanced repression by ectopic and endogenous B-Myb protein. Mutation of 10 of 22 putative cyclin A sites, which greatly reduces the effects of cyclin A on transactivation by B-Myb, had no effect on the ability of cyclin A to alleviate B-Myb-mediated repression of a2(V) collagen promoter activity. Furthermore, the stability of the mutant B-Myb protein was largely unaffected by cyclin A, although ectopic expression of cyclin A enhanced the rate of decay of wild-type B-Myb protein. Thus, the mechanisms of repression and activation appear distinct, for example, mediated by different critical phosphorylation sites or protein-protein interactions. B-Myb mutants with either deletion of aa 374-581 (B-Myb-Mut3) or C-terminal truncation beyond aa 491 (B-Myb-491) positively regulated a2(V) collagen promoter activity, and were not affected by cyclin A. Thus, our findings indicate that the ability of B-Myb to function as a repressor of matrix promoter activity is abolished by cyclin A, and maps the sites mediating negative regulation by B-Myb to the region between aa 491 and 582.
Introduction
B-Myb belongs to the myb oncogene family, which includes two other known cellular members, A-Myb and c-Myb, the proto-oncogenic counterpart of the v-Myb transforming protein. The B-myb and A-myb genes were isolated based on their homology within the DNAbinding region to c-myb (Nomura et al., 1988) . The B-myb mRNA is approximately 3.3-3.5 kb and codes for a B-Myb protein of B704 amino acids (aa) that has a molecular weight of approximately 93 kDa (Arsura et al., 1994; Marhamati and Sonenshein, 1996) . At the structural level, all members share two domains of sequence homology: the DNA-binding domain, located at the amino-terminus (Nakagoshi et al., 1993) , and a carboxyl-terminal regulatory domain, which is involved in negative regulation of Myb activity (Lane et al., 1997; Ziebold et al., 1997) . However, B-Myb lacks the acidic transactivation domain that is conserved between c-Myb and A-Myb (Foos et al., 1992) . In addition to the consensus Myb binding site (MBS) [YGR (A/C/G) GTT (G/A)] (Howe and Watson, 1991) , B-Myb is capable of recognizing a second specific consensus sequence [PuPuAAANYG] (Mizuguchi et al., 1990) .
B-Myb is important in early embryonic development as evidenced by the observation that B-myb-deficient mice die before day 6.5 of gestation, because of impaired inner cell mass formation (Tanaka et al., 1999) . Overexpression of B-Myb alters the morphology of lateral plate mesoderm in early xenopous embryos (Iwai et al., 2001) . B-Myb is expressed in all proliferating cells examined (Sala and Watson, 1999) , suggesting that it may have a more general role than c-myb or A-myb, which display more specific patterns of expression (Oh and Reddy, 1999) . Expression of B-myb RNA occurs in a cell-cycle-specific fashion, with high levels of gene transcripts observed in the late G1 and S phases (Golay et al., 1991; Lam et al., 1992; Marhamati and Sonenshein, 1996) . Interestingly, B-Myb has been shown to either activate or repress gene transcription in a celltype-as well as promoter-context-specific manner (Foos et al., 1992; Tashiro et al., 1995; Marhamati and Sonenshein, 1996; Piccinini et al., 1999) . For example, B-Myb transactivated the apolipoprotein J , murine surfactant protein-A (Bruno et al., 1999) and Bcl-2 (Grassilli et al., 1999) genes, and repressed the type I and type V collagen (Marhamati and Sonenshein, 1996; Kypreos et al., 1998 Kypreos et al., , 1999 and c-erb2 genes (Mizuguchi et al., 1995) . In particular, ectopic B-Myb expression reduced the basal activity of the COL1A1, COL1A2 and COL5A2 promoters and endogenous mRNA levels, and prevented the increase in a2(V) collagen mRNA normally seen upon growth arrest of vascular smooth muscle cells (SMCs) (Marhamati and Sonenshein, 1996; Kypreos et al., 1998 Kypreos et al., , 1999 .
Recently, B-Myb was identified as a target for cyclin A/cyclin-dependent kinase (cdk)2 kinase activity (Lane et al., 1997; Sala et al., 1997; Ziebold et al., 1997) . In particular, transactivation of the HIV-1 LTR, cdc2, CD34 and fibroblast growth factor-4 promoters by BMyb was enhanced as a result of this phosphorylation (Sala et al., 1997; Johnson et al., 2002) . Furthermore, coexpression of B-Myb and cyclin A synergistically promoted entry into the S phase in several cell lines (Lane et al., 1997; Sala et al., 1997) . A total of 22 putative cyclin A phosphorylation sites have been identified, with most of these sites located in the Cterminal half of the B-Myb protein (Bartsch et al., 1999; Johnson et al., 1999) . Mutation of 10 of these sites significantly reduced the ability of cyclin A to augment transactivation by B-Myb (Johnson et al., 1999) . More recently, an additional five sites have been implicated (Johnson et al., 2002) . Physical interaction between cyclin A and the C-terminal portion of B-Myb was demonstrated, suggesting phosphorylation is direct (Muller-Tidow et al., 2001) . Since phosphorylation was not found to affect the DNA-binding activity of B-Myb, models involving changes in protein-protein interactions have been proposed (Ziebold et al., 1997; Bessa et al., 2001) . Surprisingly, with the enhanced activity seen upon phosphorylation, cyclin A accelerated the rate of degradation of B-Myb via a ubiquitination-and proteosome-mediated pathway (Charrasse et al., 2000) . Given the effects of phosphorylation on the ability of BMyb to transactivate, here we have investigated the effects of cyclin A on the ability of B-Myb to repress gene transcription, and selected the a2(V) collagen promoter. We report that cyclin A-mediated phosphorylation of B-Myb relieves its ability to repress a2(V) collagen gene transcription, and the domain responsible for the negative regulatory effects maps to the region between aa 491 and 582 of B-Myb.
Results

Expression of cyclin A reduces repression of the a2(V) collagen promoter by B-Myb
To assess the effects of phosphorylation by cyclin A on repression by B-Myb, a B-myb expression vector was cotransfected in the absence or presence of a cyclin A expression vector, and the activity of the a2(V) collagen promoter was monitored (Figure 1a) . Expression of B-Myb alone repressed the a2(V) collagen promoter activity. In three separate experiments, a2(V) collagen promoter activity was reduced by an average of 370.5-fold upon overexpression of B-Myb, consistent with our previous findings (Kypreos et al., 1999) . Coexpression of cyclin A relieved the repression of the a2(V) collagen promoter mediated by B-Myb (Figure 1a ). In particular, cyclin A expression led to restoration of the promoter activity (1.4-fold of basal activity). In three separate experiments, B-Myb plus cyclin A yielded an average of 1.17 cultures were plated at a density of 2 Â 10 5 in six-well plates. After overnight incubation, cultures were transiently transfected, in duplicate, by lipofectamine, with 1 mg pST0.25 CAT a2(V) collagen promoter CAT reporter construct, and either 0 or 2 mg pB14 bovine B-myb expression vector, in the absence (0) or presence of 0.5 mg cyclin A expression vector, and pBluescript empty vector to make a total final concentration of 5 mg DNA. After 72 h, protein extracts were prepared, and samples containing equal amounts of protein were assessed for chloramphenicol acetyl transferase (CAT) activity. (b) Effects of a cdk2-DN. SMCs were transfected, as above, with 1 mg pST0.25 CAT a2(V) collagen promoter construct in the presence of an indicated amount of pCMVcdk2-DN expression vector. The pCMV empty vector was used to make a total final concentration of 5 mg DNA in all samples. Extracts were prepared after 72 h, and samples were normalized for equal protein assessed for CAT activity. (c) Effects of cdk2-DN on ectopic B-Myb. SMCs were transfected with 1 mg pST0.25 CAT a2(V) collagen promoter construct in the presence of the indicated amount of pCMVcdk2-DN expression vector in the absence (0) or presence of 1 mg pactWT expression vector, and processed as above Regulation of B-Myb-mediated repression C Petrovas et al 0.4-fold activity relative to the control value. Expression of cyclin A had no effect on the activity of the a2(V) collagen empty vector (data not shown). Interestingly, we noted that expression of cyclin A alone induced the promoter activity. An average 2.270.7-fold increase was obtained in three separate experiments in the absence of exogenous B-Myb, suggesting an effect on negative regulation by endogenous B-Myb of the a2(V) collagen promoter. To investigate the involvement of endogenous cyclin A/cdk2 kinase activity on a2(V) collagen promoter regulation, we performed transient transfection assays using increasing amounts of a dominant-negative cdk2 (cdk2-DN) expression vector. A dose-dependent reduction of the promoter activity was observed with a maximum decrease of 2.2-fold seen (Figure 1b) . We next tested the effects of inhibiting cdk2 on repression by ectopically expressed B-Myb. A limiting amount of human pactWT B-myb vector DNA was used, which caused only a modest reduction in promoter activity, as expected ( Figure 1c ). Inhibition of cdk2 upon expression of cdk2-DN enhanced B-Myb-mediated repression of the a2(V) collagen promoter activity 5.9-fold. Similar results were obtained with a bovine B-Myb expression vector (data not shown). Thus, inhibition of the cyclin A kinase activity enhanced repression by B-Myb. Overall, these studies indicate that cyclin A/cdk2 kinase activity ablates repression of the a2(V) collagen promoter by B-Myb.
Cyclin A reduces repression by a B-Myb mutant lacking 10 cyclin A phosphorylation sites
To begin to map the specific sites of phosphorylation, we used a construct expressing a B-Myb protein with mutation of 10 identified cyclin A phosphorylation sites (pCDNA3-10Mut expressing B-Myb-10Mut) ( Figure 2a ). Mutagenesis of these sites substantially reduced the positive effects of cyclin A on transactivation by B-Myb (Johnson et al., 1999) . Cotransfection with the pCDNA3-10Mut vector effectively inhibited a2(V) collagen promoter activity in a dose-dependent manner ( Figure 2b ). A decrease of 2.5-and 3.1-fold was seen with 2 and 4 mg pCDNA3-10Mut DNA, respectively. In three separate experiments an average decrease of 2.970.3-fold was obtained, which is essentially equal to the reduction observed with wild-type (WT) B-Myb ( Figure 1a ). These results indicate that substitution of these phosphorylation sites does not affect the ability of B-Myb to repress the activity of the a2(V) collagen promoter. Interestingly, coexpression of 0.5 mg of cyclin A expression vector was able to prevent the repression of promoter activity by B-Myb-10Mut (0.9-fold of basal level) ( Figure 2c ). To verify that the ability of cyclin A to restore the promoter activity was mediated by cdk2, cotransfection analyses were carried out with the cdk2-DN plasmid. Expression of cdk2-DN partially restored the ability of B-Myb-10Mut to repress a2(V) collagen promoter activity (Figure 2c ), indicating that cyclin A/ cdk2 kinase activity is involved in the regulation described above. Thus, the 10 sites of cyclin A/cdk2 phosphorylation in B-Myb-10Mut do not appear to be required for repression.
Cyclin A overexpression results in destabilization of WT B-Myb but not B-Myb-10Mut
Given that Charrasse et al. (2000) found that cyclin A resulted in the shortening of the half-life of decay of BMyb protein in the 293 HEK cell line, we next assessed the effects of cyclin A on the stability of WT B-Myb and B-Myb-10Mut proteins in SMCs. As an initial test, we first measured the effects of cyclin A on basal B-Myb protein levels and observed a 3.8-fold reduction in amounts of WT B-Myb protein within 24 h, consistent with the findings of Charrasse and co-workers, whereas cyclin A caused only a slight decrease in levels of BMyb-10Mut protein (1.2-fold) (data not shown). To measure specifically the effects of cyclin A on the halflife of B-Myb decay, protein extracts were prepared from cells transfected with pCDNA3WT or pCDNA3-10Mut in the absence or presence of cyclin A expression vector followed by cycloheximide treatment (Figure 3) . Densitometry of the resulting Western blots indicated that ectopic cyclin A expression enhanced the rate of decay of WT B-Myb by B2-fold, that is, the basal t 1/2 of 12.3 h was reduced to 6.3 h (Figure 3a) . Addition of the proteasome inhibitor MG132 substantially prevented this decay, as expected, whereas the calpain inhibitor calpeptin had no effect (data not shown). Thus, cyclin A increases the rate of the proteasome-mediated turnover of WT B-Myb in SMCs. In contrast, cyclin A had no apparent effect on the half-life of decay of the B-Myb10Mut molecule (Figure 3b ). Taken together, these data indicate that these 10 phosphorylation sites are essential for the acceleration of B-Myb turnover rate by cyclin A. However, they are not sufficient to block the repressive effect of B-Myb on the a2(V) collagen promoter activity, suggesting that more rapid degradation is not responsible for the observed loss of repression.
C-terminus is required for repression by B-Myb and regulation by cyclin A
We have previously observed that a mutant of B-Myb that is lacking aa 374-581 (B-Myb-Mut3) activates, rather than represses, the a2(V) collagen promoter (Kypreos et al., 1999) , suggesting that critical sites for B-Myb-mediated suppression activity are localized in this domain (Figure 4a ). Thus, we next sought to test the ability of cyclin A to affect the activity of B-Myb-Mut3 on the a2(V) collagen promoter. SMC cultures were transiently transfected with 3 mg pactMut3 construct in the absence or presence of a cyclin A expression vector, and cell lysates assayed for CAT activity (Figure 4b) . B-Myb-Mut3 alone caused a 2.7-fold induction of the a2(V) collagen promoter activity, instead of the 3-to 5-fold repression typically observed with WT B-Myb, in agreement with our previous data (Kypreos et al., 1999) . Cyclin A was not able to alter this activity, even at the higher dose of 1 mg cyclin A expression vector used (Figure 4b ). Cyclin A also did not appear to alter the stability of the protein, as assessed by the overall B-Myb-Mut3 levels (Figure 4c ). Given that the two mapped nuclear localization signals Smooth muscle and the U2-OS osteosarcoma cell line, which are easily transfected and have been widely used for studies on B-Myb phosphorylation (Lane et al., 1997; Johnson et al., 1999; Bessa et al., 2001) , were analysed. Cells were transfected with the pactMut3 vector and nuclear and cytoplasmic extracts were prepared and subjected to immunoblot analysis (Figure 5a) . A similar pattern was seen in both cell lines, with the B-Myb-Mut3 protein exhibiting substantial nuclear localization. In addition, B-Myb-Mut3 protein was also clearly detected in the cytoplasmic extracts. As controls, we probed for two cytoplasmic proteins: the p105 precursor of p50 nuclear factor (NF)-kB subunit and b-tubulin. Both were found to localize exclusively to the cytoplasm, confirming the purity of the preparations (Figure 5a ). Next, we transfected U2-OS cells with either pactMut3 or FLAG-WT B-Myb expression vector DNA and performed indirect immunofluoresence (Figure 5b ). While WT B-Myb showed an exclusively nuclear staining pattern, a nuclear and diffuse cytoplasmic staining pattern was observed in the case of B-MybMut3 (Figure 5b) . Thus, B-Myb-Mut3 displays a nuclear and cytoplasmic localization, as suggested by the work of Ishii and co-workers (Nakagoshi et al., 1993) . Taken together these results suggest that nuclear B-Myb-Mut3 transactivates the a2(V) collagen promoter. Figure 2a . (b) SMCs were transfected with 1 mg pST0.25 CAT a2(V) collagen promoter construct together with pactMut3 and pCMVcyclinA expression vector, as indicated. The pBluescript empty vector was used to make a total final concentration of 5 mg DNA. CAT activity was measured, as described in Figure 1 . (c) SMCs were transfected with either 10 mg pactWT (lane 1) or 10 mg pactMut3 (lanes 2-4) expression vector in the absence or presence of the indicated amounts of pCMVcyclinA construct. Total whole extracts were prepared and samples (20 mg) were subjected to immunoblot analysis for WT and B-Myb-Mut3, using antibodies against the N-terminus of B-Myb, as well as for b-actin, which confirmed equal loading
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The aa 491-582 domain within the C-terminus is required for repression
To further localize the region of B-Myb that mediates repression of the a2(V) collagen promoter, additional constructs encoding C-terminal truncated B-Myb molecules (aa 1-422 and aa 1-491) were used ( Figure 4a ). We performed dose-response curves to assess their effects on a2(V) collagen promoter activity and examined their nuclear localization using cellular fractionation. For BMyb-491, a dose-dependent induction of the promoter activity was observed, with a maximal activation of 5.9-fold with 3 mg B-Myb-491 expression vector (Figure 6a ). An exclusive nuclear localization of B-Myb-491 was detected by immunoblotting (Figure 6a, inset) . In contrast, only a minimal induction of a2(V) collagen promoter activity was observed with the highest dose of B-Myb-422 expression vector (1.3-fold) (Figure 6b ). This was not because of an altered localization of the B-Myb-422 molecule, as immunoblot analysis again revealed a predominant nuclear localization (Figure 6b, inset) . We next assessed the effects of cyclin A on the activity and stability of B-Myb-491. Coexpression of cyclin A had only a slight effect on the positive regulation of a2(V) collagen promoter activity by B-Myb-491 (Figure 7a ). This is in agreement with a previous study by Charrasse et al. (2000) demonstrating that the activity of a Cterminal truncated B-Myb (deletion of aa 509-704) was only slightly affected by coexpressed cyclin A. Cyclin A had no effect on B-Myb-491 protein levels as judged by immunoblot analysis of nuclear extracts from cotransfected cells (Figure 7b ). Equal loading was confirmed by analysis of b-actin levels (Figure 7b) . Thus, the failure of cyclin A to alter the ability of B-Myb-491 to repress a2(V) collagen promoter is not because of reduced levels of B-Myb protein. Taken together with the findings on B-Myb-Mut3, our data indicate that sequences located between aa 491 and 582 in the C-terminal domain are necessary for B-Myb-mediated repression, as well as the effects of cyclin A/cdk2 phosphorylation on this activity. Lastly, the region between aa 422 and 491 appears to include a domain(s) critical for B-Myb to function as a potent activator.
Discussion
Here, we report that the ability of B-Myb to function as a repressor of matrix promoter activity in SMCs can be alleviated by cyclin A/cdk2 phosphorylation, and Figure 5 The B-Myb-Mut3 protein localizes to the nucleus as well as cytoplasm. (a) Subconfluent SMC and U2-OS cell cultures were transfected with 10 mg pactMut3 expression vector. Following 72 h, nuclear and cytoplasmic protein extracts were prepared, and samples (30 mg nuclear and 30 mg cytoplasmic extracts) were subjected to immunoblot analysis for B-Myb-Mut3, p105 subunit of NFkB, b-tubulin and b-actin, which confirmed equal loading. (b) U2-OS cells were cultured in 16-well chamber glass slides and transfected with FLAG-WT B-Myb or pactMut3 expression vector. B-Myb was visualized using mouse anti-FLAG or rabbit anti-B-Myb (Santa Cruz) as the primary antibody, and either anti-mouse IgG-FITC or anti-rabbit IgG-R, respectively, as the secondary antibody Regulation of B-Myb-mediated repression C Petrovas et al requires aa 491-582 within the C-terminal region. In particular, we observed that upon ectopic expression of cyclin A, the negative regulation of a2(V) collagen promoter activity by cotransfected or endogenous BMyb was no longer detectable. Conversely, overexpression of a cdk2-DN molecule resulted in lower levels of endogenous a2(V) collagen promoter activity and enhanced repression by a cotransfected B-Myb construct. Thus, cyclinA/cdk2 kinase activity regulates repression by both transfected and endogenous B-Myb proteins. Interestingly, repression by B-Myb-10Mut was also sensitive to cyclin A phosphorylation in contrast to the effects of cyclin A on activation, which were essentially lost (Johnson et al., 2002) . These findings suggest that either the critical sites of cyclin A phosphorylation of B-Myb for repression and activation are different, or alternatively that the mechanism of cyclin A action to relieve repression may be indirect, for example, affecting a B-Myb binding partner (see the discussion below). Analysis of mutants of B-Myb revealed that deletion of the C-terminal region between aa 491 and 582 resulted in a constitutively active protein that was unaffected by cyclin A. Thus, cyclin A/cdk2-mediated phosphorylation appears to function as a master switch for B-Myb, alleviating its ability to function as a repressor, while promoting its transactivation potential.
Cyclin A/cdk2 phosphorylation does not appear to affect B-Myb DNA-binding activity (Ziebold et al., 1997; Bessa et al., 2001) , suggesting that it affects interactions with other proteins. An increasing body of evidence has indicated the dependence of B-Myb activity on its interaction with other nuclear factors for positive activation, for example, cyclin D1 (Horstmann et al., 2000) , poly-(ADP-ribose) polymerase and nucleonin (Ying et al., 2000) . More recently, Masselink et al. (2001) and Li and McDonnell (2002) have demonstrated association of B-Myb with the N-CoR and SMRT corepressor proteins, although differing results were obtained with respect to the effects of cyclin A/cdk2 on this interaction. Previously, we demonstrated that B-Myb-mediated repression of the a2(V) collagen promoter was indirect, via interaction and presumably inactivation of a positive regulatory factor, which we termed MRF-V (Kypreos et al., 1999) . Thus, our findings lead us to hypothesize that the effects of cyclin A/cdk2 on alleviating repression of the a2(V) collagen promoter by B-Myb occurs via affecting the interaction of B-Myb with another protein, for example, interaction with MRF-V, or other factors implicated in the regulation of a2(V) collagen promoter activity (Penkov et al., 2000) . Experiments are in progress to test this hypothesis. In agreement with our previous data (Kypreos et al., 1999) , the B-Myb-Mut3 molecule functioned as an activator rather than repressor of the a2(V) collagen promoter. Surprisingly, the deleted region includes the conserved region (CR) that has been described as a necessary sequence for transactivation by B-Myb (Tashiro et al., 1995) . Interestingly, this region also includes the sequences implicated both in B-Myb interaction with the repressor protein BS69 (Masselink et al., 2001) , and in mediating protein-protein interaction(s) with other cofactor(s) critical for the cell-type-specific regulation by B-Myb (Tashiro et al., 1995) . Cyclin A did not affect the transactivation activity of the B-Myb-Mut3 or B-Myb-491 molecules, suggesting either that phosphorylation sites common to these regions (aa 491-582) are essential for this activity, for example, via interaction with another nuclear repressor, or that the deleted protein functions via an alternative mechanism. Further deletion of the C-terminal sequences (i.e. aa 423-704) resulted in a protein with little or weak activation potential. Previously, Oh and Reddy (1998) determined that the C-terminal domain between aa 259 and 704 contained a domain responsible for the positive regulatory activity of B-Myb. Our findings suggest that the region between aa 422 and 491 is involved in the ability of B-Myb to function as a potent activator.
The nuclear localization of the B-Myb-Mut3 is an interesting finding since this mutant protein is missing in most of the two identified NLS domains in B-Myb, that is, NLS 1 at aa 411-418 and NLS 2 at aa 569-585 (Nakagoshi et al., 1993; Takemoto et al., 1994) . Interestingly, conflicting reports have appeared on the roles of these two NLS. Charrasse et al. (2000) described that B-Myb molecules lacking aa 509-704 localize to the nucleus. In contrast, Johnson et al. (2002) reported that two truncated molecules (deletion of aa 470-704 and aa 560-704) are primarily localized in the cytoplasm, although the mutants were not excluded from the nucleus. In addition, the NLS located in aa 411-418 was not functional in the study by Johnson et al. (2002) . In the same context, Nakagoshi et al. (1993) found that a mutant lacking the two NLS was mainly in the cytoplasm. Using immunoblot analysis, here we observed essentially exclusive nuclear localization of both B-Myb-421 and B-Myb-491 truncated molecules. Immunoblot and indirect immunofluoresence assays revealed nuclear as well as cytoplasmic localization for the B-Myb-Mut3 molecule. This mutant retains a cluster of basic amino acids (aa 583, 584) located in the second NLS. Thus, it is possible that this cluster facilitates the nuclear import, or that other, as yet unidentified, signals are involved in the nuclear targeting of B-Myb.
Materials and methods
Cell culture and treatment conditions SMC explants were derived from the aorta of female calves, as we have previously described (Beldekas et al., 1982) . Cultures were grown and maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 1% nonessential amino acids, 1% sodium pyruvate, 100 U penicillin/ml and 100 mg streptomycin/ml (Gibco). The aortic cells were used up to sixth passage. The human osteosarcoma cell line U2-OS was purchased from American Type Culture Collection, and cultured under the same conditions as the SMCs. For half-life studies, cell cultures were treated with 50 mg/ml cycloheximide (Sigma).
DNA constructs and transient transfection conditions
The expression vector for full-length bovine B-Myb (pB14) has been described previously (Marhamati and Sonenshein, 1996) . The vectors expressing human B-Myb (pactWT) and a Cterminal mutant of B-Myb (pactMut3), which contains a deletion of 626 bp (nucleotides +1246 to +1872) (B-MybMut3), were kindly provided by S Ishii (Laboratory of Molecular Genetics, RIKEN Tsukuba Institute, Ibaraki, Japan), and have been previously described (Kypreos et al., 1999) . The CAT human a2(V) collagen promoter construct (pST0.25) contains 150 bp of exon 1 and upstream sequences of 100 bp (Kypreos et al., 1999) , and was kindly provided by F Ramirez (Mt Sinai Medical School, New York, NY, USA). The expression vectors for mouse full-length B-Myb (pCDNA3WT) and a mutant lacking 10 phosphorylation sites (pCDNA3-10Mut) have been previously described (Johnson et al., 1999) . Constructs expressing mutants mouse B-Myb-422 (Bessa et al., 2001) . Expression vectors for human cyclin A (pCMVcyclinA) and cdk2-DN (pCMVcdk2-DN) were generously provided by J Xiao (Boston University Medical School, Boston, MA, USA). Bovine SMCs were transiently transfected using Lipofectamine 2000 (Gibco), according to the manufacturer's instructions, and equal amounts of total protein were subjected to CAT assay, as we have described previously (Kypreos et al., 1999) .
Protein analysis
At 72 h following transfection, whole cell extracts were prepared in RIPA buffer (50 mm Tris-HCl, pH 7.5, 150 mm NaCl, 1% Nonidet P-40 (NP-40), 0.1% SDS, 1% sodium sarcosyl, 10 mg/ml leupeptin, 1 mm phenylmethylsulfonyl fluoride, 1 mm dithiothreitol), sonicated, and debris removed by centrifugation. Alternatively, cytoplasmic extracts were prepared following incubation on ice for 10 min in cytoplasmic isolation buffer (10 mm HEPES, pH 7.5, 60mm KCl, 1 mm EDTA, 0.1% NP-40, 1 mm dithiothreitol, 1 mm phenylmethylsulfonyl fluoride). The nuclei were removed by centrifugation, and cytoplasmic samples were collected. Lysis was routinely monitored by crystal violet staining of nuclei. Nuclei extracts were prepared using extraction buffer (50 mm Tris-HCl, pH 7.5, 150 mm NaCl, 1% sodium sarcosyl, 1% NP-40, 0.1% SDS, 1 mm EDTA and protease inhibitors). Protein content was assessed using the Bio-Rad protein quantitation kit for detergent lysis, according to the manufacturer's instructions, and samples were resolved by electrophoresis in 10% polyacrylamide SDS gels. The resulting blot was incubated for 1 h with one of the following antibodies: rabbit polyclonal antibodies against the human B-Myb protein (Johnson et al., 1999) , the N-terminus of B-Myb (N-19, sc-724, Santa Cruz Biotechnology), the p50 subunit of NF-kB (sc-114, Santa Cruz Biotechnology) or a monoclonal antibody against either bactin (Sigma) or b-tubulin (Sigma). Following 1 h incubation in the appropriate anti-rabbit or anti-mouse horseradish peroxidase-conjugated antibody, the protein bands were visualized using the ECL system (Amersham). Quantitation by scanning densitometry was performed using a Kodak digital camera (Model DC120) with a computing imaging system.
Indirect immunofluorescence
U2-OS cells, cultured in 16-well chamber glass slides, were transiently transfected using Fugene 6 with 0.5 mg of either FLAG-WT B-Myb (Johnson et al., 2002) or 1 mg mutant BMyb (pact-Mut3) expression vector. The cells were fixed with 3.5% formaldehyde, permeabilized with 0.5% Triton X-100, and nonspecific binding sites were blocked with 2% bovine serum albumin in PBS. The cells were then incubated either with a rabbit antibody against the N-terminus of B-Myb or a mouse monoclonal antibody against FLAG. An anti-mouse IgG-FITC or a donkey anti-rabbit IgG-rhodamine was used as secondary-conjugated antibody (Santa Cruz Biotechnology). Slides were observed under an Axiovert 35 microscope (Zeiss, Germany).
